Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

21st Century Cures: Device Provisions

Executive Summary

Dozens of reforms impacting the medtech sector were passed by the US House Nov. 30 in a compromise version of the 21st Century Cures Act that is expected to pass the Senate and be signed by President Obama before he leaves office. Here's a breakdown of the provisions most important to device- and diagnostic-makers.

You may also be interested in...



Trump Praises Record Device Approvals, Pushes Congress To Pass 'Right-To-Try' Bills

In his Jan. 30 State of the Union address, President Trump praised US FDA for its high approval rate of devices and drugs in 2017, and urged Congress to do more by approving 'right-to-try' legislation that he says would allow terminally ill patients to gain access to experimental devices and drugs.

Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon

FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.

Combo-Product Sponsors Gain Some Favored Changes In Final Post-Market Reporting Rule

US FDA’s final rule includes several clarifications about its scope and definitions, and includes some additional reporting requirements.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel